This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports narrower-than-expected loss in Q4 while revenues marginally fall short of estimates. However, the top line shows a massive year-over-year increase.
Looking for a Growth Stock? Why It is Time to Focus on Regeneron (REGN)
by Zacks Equity Research
Regeneron (REGN) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta
by Zacks Equity Research
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing
by Zacks Equity Research
Bristol-Myers (BMY) Opdivo becomes the first and only FDA-approved PD-1 inhibitor for every four-week dosing.
Lilly, Boehringer to Expand Jardiance Heart Failure Program
by Zacks Equity Research
Lilly (LLY) and Boehringer plan to expand their clinical trial program for Jardiance in chronic heart failure through clinical trials.
Spectrum (SPPI) Q4 Loss Widens Y/Y, Sales Miss, Stock Falls
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in the fourth quarter, while it misses on revenues. Rolontis successful in phase III study.
AstraZeneca's Forxiga Label Expansion Filing Accepted in EU
by Zacks Equity Research
AstraZeneca's (AZN) submission for label expansion of diabetes drug Forxiga accepted by the European Medicines Agency.
Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink
by Zacks Equity Research
Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.
Gilead Announces Positive Data on New HIV Therapy Biktarvy
by Zacks Equity Research
Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.
FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi announced that the FDA has accepted the companies' sBLA for Dupixent for asthma with a target date of Oct 20, 2018.
Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Aduro (ADRO) reports narrower-than-expected loss in Q4. However, sales miss estimates and fall year over year on declining grant revenues.
Valeant (VRX) Down on Q4 Earnings Miss, Issues Drab '18 View
by Zacks Equity Research
Valeant (VRX) announced disappointing results in the fourth quarter. The outlook for 2018 was dismal too, which disappointed investors.
Pacira (PCRX) Posts Earnings in Q4, Revenues in Line
by Zacks Equity Research
Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.
Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress
by Zacks Equity Research
Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.
Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The top line however, drops year over year.
Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down
by Zacks Equity Research
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses
by Zacks Equity Research
Radius Health (RDUS) reported a wider-than-expected loss in the fourth quarter due to higher operating expenses related to the commercialization of Tymlos.
Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Down Y/Y
by Zacks Equity Research
Bayer AG's (BAYRY) fourth-quarter 2017 core earnings per share from continuing operations beat estimates.
Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
by Zacks Equity Research
Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.
AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.